What is the treatment followed for lung cancer?

Hi,

Welcome to icliniq.com.

Please say about the histopathology report. Please explain the condition briefly. Please state whether there was a mutation done before starting Gefitinib. All these things are essential for deciding the response to Gefitinib. In general, on taking Gefitinib, the average survival is 13 to 14 months. But some patients have long-term survival for three to four years. Some patients do well for five to six years.

Usually, Gefitinib is well tolerated. The most common side effects are skin rash and acne. Rarely, it can cause hepatitis or pneumonitis which is manageable with drug discontinuation for a few weeks. I recommend doing a PET (positron emission tomography) scan every three months. Have a look over the drug response. Please send your report so that I can guide you further.

Hi,

Welcome back to icliniq.com.

It gives me a clear picture.

Hi,

Welcome back to icliniq.com.

I have gone through the attachment (attachment removed to protect patient identity). I am puzzled regarding the thyroid mass and multiple lymph nodes. The PET (positron emission tomography) scan suggest lung cancer in the fourth stage as there is a pleural based nodule. She is a good candidate for having Gefitinib based on genome testing. Please explain about the condition of tuberculosis and the medication taken for tuberculosis.

Hi,

Welcome back to icliniq.com.

The histopathology report shows TTF-1 (thyroid transcription factor), CK7 (cytokeratin7) positive and thyroglobulin negative. It is lung cancer. Now, the dose of Gefitinib has to be increased as ATT can reduce the effectiveness of Gefitinib. It is important.